Sertindole

DB06144

small molecule approved investigational withdrawn

Deskripsi

Sertindole, a neuroleptic, is one of the newer antipsychotic medications available. Serdolect is developed by the Danish pharmaceutical company H. Lundbeck. It is a phenylindole derivative used in the treatment of schizophrenia. It was first marketed in 1996 in several European countries before being withdrawn two years later because of numerous cardiac adverse effects. It has once again been approved and should soon be available on the French and Australian market.

Struktur Molekul 2D

Berat 440.941
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 3 days
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Orally available.

Metabolisme

Hepatic. Sertindole is metabolized by cytochrome P450 isoenzymes CYP 2D6 and CYP 3A4.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

1065 Data
Buprenorphine Sertindole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Sertindole.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Sertindole.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Sertindole.
Hydrocodone Sertindole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Magnesium sulfate The therapeutic efficacy of Sertindole can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Sertindole may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Sertindole may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Sertindole.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Sertindole.
Orphenadrine Sertindole may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Sertindole may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Sertindole.
Rotigotine Sertindole may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Sertindole.
Sodium oxybate Sertindole may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Sertindole may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Sertindole.
Thalidomide Sertindole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Sertindole may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Amisulpride Sertindole may increase the antipsychotic activities of Amisulpride.
Methylphenidate The risk or severity of adverse effects can be increased when Sertindole is combined with Methylphenidate.
Metoclopramide The risk or severity of adverse effects can be increased when Metoclopramide is combined with Sertindole.
Quinagolide The therapeutic efficacy of Quinagolide can be decreased when used in combination with Sertindole.
Sulpiride Sertindole may increase the antipsychotic activities of Sulpiride.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Sertindole.
Lithium citrate Lithium citrate may increase the neurotoxic activities of Sertindole.
Lithium hydroxide Lithium hydroxide may increase the neurotoxic activities of Sertindole.
Mequitazine Sertindole may increase the arrhythmogenic activities of Mequitazine.
Linezolid The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Sertindole.
Dicoumarol The risk or severity of adverse effects can be increased when Sertindole is combined with Dicoumarol.
Phenindione The risk or severity of adverse effects can be increased when Sertindole is combined with Phenindione.
Coumarin The risk or severity of adverse effects can be increased when Sertindole is combined with Coumarin.
Tioclomarol The risk or severity of adverse effects can be increased when Sertindole is combined with Tioclomarol.
Warfarin The risk or severity of adverse effects can be increased when Sertindole is combined with Warfarin.
Phenprocoumon The risk or severity of adverse effects can be increased when Sertindole is combined with Phenprocoumon.
Acenocoumarol The risk or severity of adverse effects can be increased when Sertindole is combined with Acenocoumarol.
4-hydroxycoumarin The risk or severity of adverse effects can be increased when Sertindole is combined with 4-hydroxycoumarin.
(R)-warfarin The risk or severity of adverse effects can be increased when Sertindole is combined with (R)-warfarin.
Ethyl biscoumacetate The risk or severity of adverse effects can be increased when Sertindole is combined with Ethyl biscoumacetate.
Fluindione The risk or severity of adverse effects can be increased when Sertindole is combined with Fluindione.
Clorindione The risk or severity of adverse effects can be increased when Sertindole is combined with Clorindione.
Diphenadione The risk or severity of adverse effects can be increased when Sertindole is combined with Diphenadione.
(S)-Warfarin The risk or severity of adverse effects can be increased when Sertindole is combined with (S)-Warfarin.
Mirabegron The serum concentration of Sertindole can be increased when it is combined with Mirabegron.
Mirtazapine Sertindole may increase the serotonergic activities of Mirtazapine.
Ethanol Sertindole may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Sertindole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Sertindole.
Zimelidine The risk or severity of adverse effects can be increased when Sertindole is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Sertindole is combined with Dapoxetine.
Seproxetine The risk or severity of adverse effects can be increased when Sertindole is combined with Seproxetine.
Citalopram The risk or severity of QTc prolongation can be increased when Sertindole is combined with Citalopram.
Sertraline The risk or severity of adverse effects can be increased when Sertindole is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Sertindole is combined with Sibutramine.
Milnacipran The risk or severity of adverse effects can be increased when Sertindole is combined with Milnacipran.
Desvenlafaxine The risk or severity of serotonin syndrome can be increased when Desvenlafaxine is combined with Sertindole.
Levomilnacipran The risk or severity of serotonin syndrome can be increased when Sertindole is combined with Levomilnacipran.
Indalpine The risk or severity of adverse effects can be increased when Sertindole is combined with Indalpine.
Alaproclate The risk or severity of adverse effects can be increased when Sertindole is combined with Alaproclate.
Carbidopa The therapeutic efficacy of Carbidopa can be decreased when used in combination with Sertindole.
Cabergoline The therapeutic efficacy of Cabergoline can be decreased when used in combination with Sertindole.
Tolcapone The therapeutic efficacy of Tolcapone can be decreased when used in combination with Sertindole.
Metixene The therapeutic efficacy of Metixene can be decreased when used in combination with Sertindole.
Trihexyphenidyl The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Sertindole.
Procyclidine The therapeutic efficacy of Procyclidine can be decreased when used in combination with Sertindole.
Profenamine The therapeutic efficacy of Profenamine can be decreased when used in combination with Sertindole.
Entacapone The therapeutic efficacy of Entacapone can be decreased when used in combination with Sertindole.
Lisuride The therapeutic efficacy of Lisuride can be decreased when used in combination with Sertindole.
Apomorphine The therapeutic efficacy of Apomorphine can be decreased when used in combination with Sertindole.
Biperiden The therapeutic efficacy of Biperiden can be decreased when used in combination with Sertindole.
Amantadine The therapeutic efficacy of Amantadine can be decreased when used in combination with Sertindole.
Memantine The therapeutic efficacy of Memantine can be decreased when used in combination with Sertindole.
Pergolide The therapeutic efficacy of Pergolide can be decreased when used in combination with Sertindole.
Levodopa The therapeutic efficacy of Levodopa can be decreased when used in combination with Sertindole.
Rasagiline The therapeutic efficacy of Rasagiline can be decreased when used in combination with Sertindole.
3,5-Dinitrocatechol The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Sertindole.
Etilevodopa The therapeutic efficacy of Etilevodopa can be decreased when used in combination with Sertindole.
Safinamide The therapeutic efficacy of Safinamide can be decreased when used in combination with Sertindole.
Ifenprodil The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Sertindole.
Dexetimide The therapeutic efficacy of Dexetimide can be decreased when used in combination with Sertindole.
Opicapone The therapeutic efficacy of Opicapone can be decreased when used in combination with Sertindole.
Piribedil The therapeutic efficacy of Piribedil can be decreased when used in combination with Sertindole.
Benserazide The therapeutic efficacy of Benserazide can be decreased when used in combination with Sertindole.
Tropatepine The therapeutic efficacy of Tropatepine can be decreased when used in combination with Sertindole.
Melevodopa The therapeutic efficacy of Melevodopa can be decreased when used in combination with Sertindole.
Dihydroergocryptine The therapeutic efficacy of Dihydroergocryptine can be decreased when used in combination with Sertindole.
Phenglutarimide The therapeutic efficacy of Phenglutarimide can be decreased when used in combination with Sertindole.
Mazaticol The therapeutic efficacy of Mazaticol can be decreased when used in combination with Sertindole.
Etybenzatropine The therapeutic efficacy of Etybenzatropine can be decreased when used in combination with Sertindole.
Budipine The therapeutic efficacy of Budipine can be decreased when used in combination with Sertindole.
Bornaprine The therapeutic efficacy of Bornaprine can be decreased when used in combination with Sertindole.
Etanautine The therapeutic efficacy of Etanautine can be decreased when used in combination with Sertindole.
Dexpramipexole The therapeutic efficacy of Dexpramipexole can be decreased when used in combination with Sertindole.
Bromocriptine The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Sertindole.
Methylene blue Sertindole may increase the serotonergic activities of Methylene blue.
Trospium The metabolism of Sertindole can be decreased when combined with Trospium.
Cyproheptadine The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Sertindole.
Propiomazine The risk or severity of CNS depression can be increased when Propiomazine is combined with Sertindole.
Tolterodine The metabolism of Sertindole can be decreased when combined with Tolterodine.

Target Protein

D(2) dopamine receptor DRD2
5-hydroxytryptamine receptor 2A HTR2A
5-hydroxytryptamine receptor 2C HTR2C
5-hydroxytryptamine receptor 6 HTR6
Voltage-gated inwardly rectifying potassium channel KCNH2 KCNH2
Alpha-1A adrenergic receptor ADRA1A
Alpha-1B adrenergic receptor ADRA1B
Alpha-1D adrenergic receptor ADRA1D

Referensi & Sumber

Artikel (PubMed)
  • PMID: 15989577
    Kane JM, Tamminga CA: Sertindole (Serdolect): preclinical and clinical findings of a new atypical antipsychotic. Expert Opin Investig Drugs. 1997 Nov;6(11):1729-41.
  • PMID: 16034864
    Lewis R, Bagnall AM, Leitner M: Sertindole for schizophrenia. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD001715.
  • PMID: 16192844
    Perquin LN: Treatment with the new antipsychotic sertindole for late-occurring undesirable movement effects. Int Clin Psychopharmacol. 2005 Nov;20(6):335-8.
  • PMID: 16529528
    Murdoch D, Keating GM: Sertindole : a review of its use in schizophrenia. CNS Drugs. 2006;20(3):233-55.
  • PMID: 17458045
    Authors unspecified: Sertindole: new drug. Another "atypical" neuroleptic; QT prolongation. Prescrire Int. 2007 Apr;16(88):59-62.
  • PMID: 16925508
    Lindstrom E, Levander S: Sertindole: efficacy and safety in schizophrenia. Expert Opin Pharmacother. 2006 Sep;7(13):1825-34.
  • PMID: 16952163
    Hertel P: Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: mechanism of action. Synapse. 2006 Dec 1;60(7):543-52.

Contoh Produk & Brand

Produk: 0 • International brands: 2
International Brands
  • Serdolect
  • SerLect

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul